Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Summary by Relevant Sections Class Action Lawsuit Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx and its executives made false statements and failed to disclose critical information about the Phase III Orbit study, which did not achieve statistically significant results [1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a false impression of having reliable data on setrusumab's effects while downplaying the risks associated with the Phase III Orbit study [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study failed to achieve statistical significance, leading to a stock price drop of over 25% [1] - Further, on December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies did not meet primary endpoints, resulting in a stock price decline of more than 42% [1] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek lead plaintiff status, representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1]

Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Great Elm Capital Corp. regarding possible recovery of investor losses under federal securities laws due to the company's statements about its exposure to First Brands Capital Group LLC following First Brands' bankruptcy [1][3]. Group 1: Investigation Details - The investigation focuses on whether Great Elm Capital's executive officers made misleading statements about the company's financial exposure related to First Brands Capital Group LLC [3]. - Investors who purchased Great Elm Capital securities and suffered losses are encouraged to join the investigation [2]. Group 2: About Johnson Fistel, PLLP - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with offices across multiple states [4]. - The firm has a strong track record, having recovered approximately $90.725 million for clients in securities class action lawsuits, and has been recognized as a top plaintiffs' securities law firm multiple times [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines after revelations of financial discrepancies [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it involves purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025 [1]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Ardent Health and its executives [1]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, leading to inflated financial reports [3]. - It is claimed that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, resulting in materially misleading financial positions [3]. - The company allegedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in the New Mexico market [3]. Group 3: Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third-quarter revenue due to revised accounts receivable collectability assessments [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Beyond Meat, Inc. (NASDAQ: BYND) ("Beyond Meat" or the "Company") on behalf of investors who purchased or otherwise acquired Beyond Meat securities during the period from February 27, 2025 through November 11, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Beyond Meat securities during the Class Peri ...

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. (NASDAQ: METC) for allegedly misleading investors about the development progress of its projects, particularly the Brook Mine in Wyoming, leading to a significant drop in stock price following the revelation of these claims [1]. Company Overview - Ramaco Resources, Inc. is headquartered in Lexington, Kentucky, and operates coal and mineral development projects in the United States [1]. Lawsuit Details - The lawsuit pertains to investors who purchased Ramaco securities between July 31, 2025, and October 23, 2025, with a deadline of March 31, 2026, for potential lead plaintiff appointments [1]. - The complaint alleges that Ramaco overstated development progress at the Brook Mine, which was described as a "hoax" and a "Potemkin Mine" by Wolfpack Research, indicating no significant mining activity had occurred since its groundbreaking [1]. Stock Market Impact - Following the report by Wolfpack Research on October 23, 2025, Ramaco's stock price fell by $3.81, nearly 10%, closing at $36.01 per share, with unusually high trading volume [1].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading financial statements and inadequate internal controls during the specified class period from August 7, 2024, to February 9, 2026 [1][3]. Company Overview - Kyndryl operates as a technology services company and IT infrastructure services provider [2]. Allegations of the Lawsuit - The lawsuit alleges that Kyndryl's financial statements during the class period were materially misstated [3]. - It is claimed that Kyndryl lacked adequate internal controls and failed to disclose issues related to these controls [3]. - Kyndryl is accused of being unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 [3]. Recent Developments - On February 9, 2026, Kyndryl filed a Notification of Late Filing, indicating it could not file its Quarterly Report on time [4]. - The company disclosed that it is reviewing its cash management practices and internal controls following requests from the SEC [4]. - Kyndryl anticipates reporting material weaknesses in its internal control over financial reporting for the relevant periods [4]. - Key executives, including the Chief Financial Officer and General Counsel, have departed from the company [4]. - Following these announcements, Kyndryl's stock price fell by 55% [4]. Legal Process - Investors who purchased Kyndryl securities during the class period can seek appointment as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6].

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ: CRWV) (“CoreWeave” or the “Company”) on behalf of investors who purchased or otherwise acquired CoreWeave securities during the period from March 28, 2025 through December 15, 2025 (the “Class Period”), inclusive. Investor Deadline: Investors who purchased CoreWeave securities during the Class Period may, no later than March 13 ...

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging that the company's IPO registration statement significantly understated the risks associated with its loss reserves [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased Klarna securities from September 7, 2025, to December 22, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until February 20, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Klarna's share price has declined from the IPO price of $40 per share to approximately $31.31 per share at the time of the lawsuit [3]. - The complaint claims that the company was aware or should have been aware of the high-risk profile of its customers, which could lead to increased loss reserves shortly after the IPO [3]. Group 3: Company Overview - Klarna is a leading global fintech company based in Stockholm, Sweden, specializing in Buy Now, Pay Later (BNPL) solutions [2].

Core Viewpoint - The article discusses a class action lawsuit against NuScale Power Corporation, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding its commercialization partnership with ENTRA1 Energy LLC and the financial implications of its operations [1][3]. Company Overview - NuScale Power Corporation is involved in the development of small modular nuclear reactors, specifically the NuScale Power Module (NPM), aimed at generating energy within larger power plants [2]. - The company entered a global commercialization partnership with ENTRA1 Energy LLC, which was expected to facilitate the deployment of its NPM technology [2]. Allegations of the Lawsuit - The lawsuit claims that NuScale and its executives made false statements about ENTRA1's capabilities, failing to disclose that ENTRA1 had no significant experience in building or operating nuclear power projects [3]. - It is alleged that NuScale's reliance on ENTRA1 exposed the company to undisclosed risks related to commercialization and regulatory challenges [3]. Financial Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses, which rose over 3,000% to $519 million from $17 million year-over-year, primarily due to a $495 million payment to ENTRA1 [4]. - The company's quarterly net loss surged to $532 million, up from $46 million in the previous year, following the announcement of these expenses [4]. - Following the revelation of these financial issues, NuScale's Class A shares dropped more than 12% over a two-day trading period [4]. Legal Process - Investors who purchased NuScale Class A common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the past five years [7].